Bryan Hanson
Chief Executive Officer at Zimmer Biomet
All right. Thanks,Keri, and thanks to everyone for joining us on the call this morning. Hey, we don't get the opportunity to do this too often. So I'm going to take advantage of it. And I'm just going to start the call by simply saying this was a phenomenal quarter where pretty much everything went better than expected. And importantly, as a result of that momentum, we are significantly raising our full year top and bottom line outlook, which Suky is going to talk about in just a minute. With that said, and maybe taking a step back.
For today's call, I'll talk more about our Q1 performance and the drivers of that performance. And then Suky will get into more details for the quarter and importantly, also our financial guidance for the rest of the year. And then we'll make sure that we save plenty of time for your questions, which we look forward to addressing. But before we do any of that, I just want to take a minute to speak directly and personally to the ZB team and really truly say thank you for yet again, you have delivered beyond our expectations.
And I'm very proud of what this team is doing to navigate an environment that, while improving, there's no question it's improving, it is still fluid. And it presents us with challenges that, quite frankly, seen like daily challenges. And it is truly impressive how you're navigating that environment right now. And I'm very proud of the dedication, the resilience and the innovative thinking that you're bringing to your roles each and every day. It is truly making a difference.
But I'm most proud of how together and I do mean together, we are living the ZB mission to alleviate pain and improve the quality of life for people around the world. And as we know, we do that every eight seconds, 24 hours a day, seven days a week, which is really what it's all about in the first place. So thank you. Thank you for what you do for ZB. Thank you for what you do for our customers and most of all, and most importantly, what you do for our patients, the patients that we serve every day.
Okay. So let's take a look now at the first quarter. And as some of you may recall, coming into the year, our guidance assumed that Q1 would have the easiest comp of the year. But would also experience some headwinds from both staffing and COVID-related challenges that we felt would put pressure on elective procedures during the quarter. We also assumed that there would be a pretty high level of supply pressure in the first quarter.
Our assumptions also believed that all three of these headwind variables would then improve throughout the year, providing less impact to the business. But then outside of the easy comp, Q1 would be pretty bumpy. Okay. So what actually happened in the quarter and why was it considerably stronger than we expected? Well, first and foremost, procedure recovery was much better than we anticipated, really having almost no material or meaningful impact from COVID or staffing challenges in the quarter.
And second, we manage the supply constrained environment better than we originally anticipated. Make no mistake, supply is a real problem and it's putting pressure on the business. But this team has done an excellent job managing that environment, probably leveraging some muscle memory from the past. And then third, and I think really importantly, our team's execution and traction with our new product innovation is even stronger than we anticipated. And that's important because it's going to continue to provide benefit to the rest of the year. And so because of this, we saw another quarter of very positive year-over-year momentum in large joints with our global hip and knee businesses growing approximately 13% and 18% on an ex FX basis.
Our overall SET category grew more than 6%. Driven by strong low double-digit performance in our growth drivers in set, which we've talked about before, being sports, CMFT and upper extremities. And then this was partially offset, as expected, from headwinds from our Restorative Therapies business, where these headwinds will anniversary. And as you remember, these are reimbursement change headwinds that we have in that business, they should anniversary by the back half of this year.
And then finally, our other category grew 11% in the quarter. So needless to say, it was a pretty strong quarter. The momentum is real in this business, and our confidence is extremely high. And there's good reason for this confidence. If we just think about this quarter alone, we officially launched our new cementless knee form factor at Persona OsseoTi and this is adding to the Persona family and really strategically rounding out that portfolio. And this new Kel-design tray is extremely versatile. It's anatomic because it is the Persona family, and it's stable. And it's the only need that you could do a cemented or cementless procedure with an interoperative decision possible for the surgeon. And that's a big deal.
We believe that this will enhance the potential for cementless penetration because surgeons can go into a questionable bone quality procedure with the intent to use cementless, but then they have the ability to pivot back to cemented at the bone quality isn't there. And for this reason and a lot of other reasons, customer feedback so far has been extremely positive as we've launched this product.
And as you may know, our cementless penetration is already in the mid-teens, but we believe that this can get to 50% or higher penetration. And we're excited about that. And we truly do believe that this premium product can accelerate that growth for ZB and is already doing so. It's still early days. Our full launch is planned for the middle of this year as more sets become available. Make no mistake, this is a real driver for not just our knee franchise but for the overall company. So we're very excited.
As you remember, back in February, we also closed our acquisition of Embody, which is providing access to differentiated products and an innovative pipeline for our sports medicine business. And this investment helps expand ZB's presence in this very attractive high-growth market while also in that market, serving our customers and our patients better. And this, combined with a very strong innovation pipeline that we have in sports and the dedicated commercial channel that we put into place gives us continued confidence in our global sports franchise. And if you rack the AAOS meeting, you would have seen that we previewed our HAMR product, which is designed to ensure consistent and reproducible compaction for hip procedures while allowing the surgeon to dial up or dial back the force of the strike depending on the individual patient need. And this ability to be more personalized, actually differentiates HAMR versus other compaction devices on the market.
So needless to say, we're excited about this differentiated product. We believe this could actually increase not only the consistency for surgeons, but also the procedure efficiency, which is really important right now. and our current expectation is to launch HAMR in the third quarter of this year. And if you just look at these combined products, this is actually building on other launches that we've talked about, the Persona iQ, Hip Insights, the Identity shoulder system.
And in total, we've introduced more than 50, 5-0 new products from 2018 through the end of 2022, with the majority of those products coming in markets growing 4% or faster. And we're geared to continue that momentum. It doesn't stop here. With another 40, 4-0 planned product launches between this year and the end of 2025, again, with the majority of those products to be launched in 4%-plus growth markets. And this shift not only continues the transformation of our product portfolio, it gives us short-term revenue growth, but it also improves our weighted average market growth. And ultimately, as a result of that gives us more confidence that our markets and our portfolio mix positions the company for sustainable mid-single-digit growth.
And with this kind of traction around our product pipeline, increasing strength of our balance sheet and our team members' ability to execute, ZB continues to be well positioned to deliver value today and in the future and achieve our mission as a company.
And with that, I'm going to turn the call over to Suky to take a closer look at Q1 and our latest expectations for 2023. Okay, Suky?
